Mafosfamide lysine

InformationLY2857785 is a type I reversible and competitive ATP kinase inhibitor againstCDK9(IC50=0.011 μM) and also inhibits other transcription kinasesCDK8(IC50=0.016 μM) andCDK7(IC50=0.246 μM).TargetsCDK9 (Cell-free assay): CDK8 (Cell-free

LY3022859 (anti-TGFBR2) is a monoclonal antibody directed against transforming growth factor-beta receptor type II (TGF-beta RII) with potential antineoplastic activity.

LY3022859 (anti-TGFBR2) is a monoclonal antibody directed against transforming growth factor-beta receptor type II (TGF-beta RII) with potential antineoplastic activity.

LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase ( GARFT ), with a K i of 6.5 nM, and has antitumor activity.In VitroLY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), with a K i of

LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase ( GARFT ), with a K i of 6.5 nM, and has antitumor activity.In VitroLY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), with a K i of

LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase ( GARFT ), with a K i of 6.5 nM, and has antitumor activity.In VitroLY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), with a K i of

LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase ( GARFT ), with a K i of 6.5 nM, and has antitumor activity.In VitroLY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), with a K i of

LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase ( GARFT ), with a K i of 6.5 nM, and has antitumor activity.In VitroLY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), with a K i of

InformationLY3405105 LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity.

InformationLY3405105 LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity.

InformationLY3405105 LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity.

InformationLY3405105 LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity.